CL2013000335A1 - Forma altamente cristalina de valsartan; proceso para prepararla; composicion farmaceutica que la comprende y uso en el tratamiento de la hipertension. - Google Patents
Forma altamente cristalina de valsartan; proceso para prepararla; composicion farmaceutica que la comprende y uso en el tratamiento de la hipertension.Info
- Publication number
- CL2013000335A1 CL2013000335A1 CL2013000335A CL2013000335A CL2013000335A1 CL 2013000335 A1 CL2013000335 A1 CL 2013000335A1 CL 2013000335 A CL2013000335 A CL 2013000335A CL 2013000335 A CL2013000335 A CL 2013000335A CL 2013000335 A1 CL2013000335 A1 CL 2013000335A1
- Authority
- CL
- Chile
- Prior art keywords
- valsartan
- hypertension
- prepare
- treatment
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Forma altamente cristalina de valsartán; proceso para prepararla; composición farmacéutica que la comprende y uso en el tratamiento de la hipertensión.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37028510P | 2010-08-03 | 2010-08-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2013000335A1 true CL2013000335A1 (es) | 2013-06-14 |
Family
ID=44645072
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2013000335A CL2013000335A1 (es) | 2010-08-03 | 2013-02-01 | Forma altamente cristalina de valsartan; proceso para prepararla; composicion farmaceutica que la comprende y uso en el tratamiento de la hipertension. |
Country Status (18)
Country | Link |
---|---|
US (1) | US20130137737A1 (es) |
EP (1) | EP2601180A1 (es) |
JP (1) | JP2013532707A (es) |
KR (1) | KR20130139863A (es) |
CN (1) | CN103052630A (es) |
AR (1) | AR082435A1 (es) |
AU (1) | AU2011287616A1 (es) |
BR (1) | BR112013002589A2 (es) |
CA (1) | CA2806657A1 (es) |
CL (1) | CL2013000335A1 (es) |
CO (1) | CO6670580A2 (es) |
EC (1) | ECSP13012459A (es) |
MA (1) | MA34580B1 (es) |
MX (1) | MX2013001251A (es) |
RU (1) | RU2013109365A (es) |
SG (1) | SG187007A1 (es) |
TW (1) | TW201206428A (es) |
WO (1) | WO2012016969A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103739564A (zh) * | 2012-02-20 | 2014-04-23 | 中国科学院上海药物研究所 | 缬沙坦的多晶型及其制备方法 |
CN103435567B (zh) * | 2013-09-09 | 2015-08-26 | 山东新华制药股份有限公司 | 缬沙坦的精制方法 |
CN105801506A (zh) * | 2014-12-30 | 2016-07-27 | 天津法莫西医药科技有限公司 | 缬沙坦新晶型及其制备方法 |
JP2016150917A (ja) * | 2015-02-17 | 2016-08-22 | 株式会社トクヤマ | バルサルタンの結晶の製造方法 |
CN105777660A (zh) * | 2016-03-29 | 2016-07-20 | 潍坊盛瑜药业有限公司 | 缬沙坦晶型e的诱导结晶工艺及应用 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PH30484A (en) | 1990-02-19 | 1997-05-28 | Ciba Geigy | Acy compounds pharmaceutical composition containing said compound and method of use thereof |
CN1137887C (zh) * | 2000-04-07 | 2004-02-11 | 常州四药制药有限公司 | 一种合成缬沙坦的改进方法 |
DE60135560D1 (de) | 2000-07-19 | 2008-10-09 | Novartis Ag | Valsartan salze |
US6869970B2 (en) | 2002-02-04 | 2005-03-22 | Novartis Ag | Crystalline salt forms of valsartan |
WO2003089417A1 (en) * | 2002-04-15 | 2003-10-30 | Dr. Reddy's Laboratories Limited | Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- [2’-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl] amine (valsartan) |
GB0222056D0 (en) * | 2002-09-23 | 2002-10-30 | Novartis Ag | Process for the manufacture of organic compounds |
CN1788004A (zh) * | 2003-03-17 | 2006-06-14 | 特瓦制药工业有限公司 | 缬沙坦的多晶型 |
ES2238022T3 (es) | 2003-03-17 | 2008-11-01 | Teva Pharmaceutical Industries Ltd. | Poliformos de valsartan. |
CZ298685B6 (cs) * | 2003-05-15 | 2007-12-19 | Zentiva, A.S. | Zpusob výroby N-(1-oxopentyl)-N-[[2´-(1H-tetrazol-5-yl)[1,1´-bifenyl]-4-yl]methyl]-L-valinu (valsartanu) |
ITMI20032267A1 (it) * | 2003-11-21 | 2005-05-22 | Dinamite Dipharma S P A In Forma A Bbreviata Diph | Procdimento per la preparzione di valsartan e suoi intermedi |
US20060270723A1 (en) | 2005-01-11 | 2006-11-30 | Tamas Koltai | Process for preparing amorphous valsartan |
EP1896433A4 (en) * | 2005-05-25 | 2010-06-02 | Ipca Lab Ltd | NOVEL CRYSTALLINE FORMS OF (S) -N- (1-CARBOXY-2-METHYL-PROP-1-YL) -N-PENTANOYL-N- [2 '- (1H-TETRAZOL-5-YL) BI-PHENYL-4 ylmethyl] amine |
ITMI20051989A1 (it) * | 2005-10-20 | 2007-04-21 | Dipharma Spa | Procedimerntyo per la preparazione di composti antagonisti di angiotensina ii |
WO2007069271A2 (en) * | 2005-10-31 | 2007-06-21 | Alembic Limited | Process for the purification of (s) -n- (l-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- [2' - (1h-tetraz0l-5-yl) bipheny l-4 -ylmethyl] -amine (valsartan) |
CN1844110B (zh) * | 2005-12-09 | 2010-07-14 | 浙江天宇药业有限公司 | 高光学纯度的缬沙坦的合成方法 |
CN101270096B (zh) * | 2007-03-22 | 2011-08-03 | 浙江华海药业股份有限公司 | 一种合成缬沙坦的方法 |
CN100522953C (zh) * | 2007-04-03 | 2009-08-05 | 浙江天宇药业有限公司 | 一种缬沙坦的新合成方法 |
ES2316281B1 (es) * | 2007-05-14 | 2010-02-09 | Quimica Sintetica, S.A. | Procedimiento para la preparacion de valsartan. |
CN101362728B (zh) * | 2008-08-22 | 2011-07-20 | 北京赛科药业有限责任公司 | 一种缬沙坦的合成方法 |
CN101768128B (zh) * | 2009-01-05 | 2012-10-10 | 浙江华海药业股份有限公司 | 一种含10%以上异构体的缬沙坦的精制方法 |
CN101475540B (zh) * | 2009-01-22 | 2011-05-11 | 江苏德峰药业有限公司 | 一种缬沙坦的制备方法 |
CN101735164A (zh) * | 2009-12-22 | 2010-06-16 | 北京赛科药业有限责任公司 | 缬沙坦中杂质f的研究及控制方法 |
-
2011
- 2011-08-01 AR ARP110102771A patent/AR082435A1/es unknown
- 2011-08-01 MX MX2013001251A patent/MX2013001251A/es not_active Application Discontinuation
- 2011-08-01 KR KR1020137005256A patent/KR20130139863A/ko not_active Application Discontinuation
- 2011-08-01 AU AU2011287616A patent/AU2011287616A1/en not_active Abandoned
- 2011-08-01 EP EP11752132.8A patent/EP2601180A1/en not_active Withdrawn
- 2011-08-01 CN CN2011800380433A patent/CN103052630A/zh active Pending
- 2011-08-01 RU RU2013109365/04A patent/RU2013109365A/ru not_active Application Discontinuation
- 2011-08-01 BR BR112013002589A patent/BR112013002589A2/pt not_active IP Right Cessation
- 2011-08-01 JP JP2013522227A patent/JP2013532707A/ja not_active Withdrawn
- 2011-08-01 MA MA35701A patent/MA34580B1/fr unknown
- 2011-08-01 WO PCT/EP2011/063254 patent/WO2012016969A1/en active Application Filing
- 2011-08-01 SG SG2013001888A patent/SG187007A1/en unknown
- 2011-08-01 CA CA2806657A patent/CA2806657A1/en not_active Abandoned
- 2011-08-01 US US13/813,181 patent/US20130137737A1/en not_active Abandoned
- 2011-08-02 TW TW100127455A patent/TW201206428A/zh unknown
-
2013
- 2013-02-01 CO CO13019553A patent/CO6670580A2/es not_active Application Discontinuation
- 2013-02-01 CL CL2013000335A patent/CL2013000335A1/es unknown
- 2013-02-25 EC ECSP13012459 patent/ECSP13012459A/es unknown
Also Published As
Publication number | Publication date |
---|---|
ECSP13012459A (es) | 2013-03-28 |
SG187007A1 (en) | 2013-02-28 |
CO6670580A2 (es) | 2013-05-15 |
BR112013002589A2 (pt) | 2019-09-24 |
AR082435A1 (es) | 2012-12-05 |
MA34580B1 (fr) | 2013-10-02 |
WO2012016969A1 (en) | 2012-02-09 |
JP2013532707A (ja) | 2013-08-19 |
RU2013109365A (ru) | 2014-09-10 |
KR20130139863A (ko) | 2013-12-23 |
TW201206428A (en) | 2012-02-16 |
US20130137737A1 (en) | 2013-05-30 |
AU2011287616A1 (en) | 2013-02-28 |
CN103052630A (zh) | 2013-04-17 |
MX2013001251A (es) | 2013-03-18 |
EP2601180A1 (en) | 2013-06-12 |
CA2806657A1 (en) | 2012-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP13012844A (es) | Composición efervescente en forma sólida para uso en aplicaciones vaginales para el tratamiento de infecciones vaginales | |
GT201400147A (es) | Pirimidinas y triazinas fusionadas sustituidas y su uso | |
GT201400111A (es) | Triazolopiridinas sustituidas | |
SMT201500148B (it) | Composizioni per uso nel trattamento di infezioni virali | |
GT201400033A (es) | Pirimidinas anilladas sustituidas y uso de las mismas | |
CL2014001158A1 (es) | Compuestos derivados de piperazina alquilados; composicion farmaceutica que los comprende; proceso para preparar la composicion farmaceutica; kit y uso en el tratamiento de trastornos inmunes, cancer, enfermedades cardiovasculares, inflamacion, entre otros. | |
CL2013001947A1 (es) | Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona. | |
BR112013016299A2 (pt) | artigo abrasivo; e método para formar o mesmo | |
ECSP13012534A (es) | Composición farmacéutica | |
UY33754A (es) | Monobactamas | |
UY34008A (es) | ?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?. | |
CL2013000455A1 (es) | Compuestos derivados oxadiazol, inhibidores de la produccion de leucotrienos; composicion farmaceutica que lo comprende; y su uso en el tratamiento de enfermedades cardiovasculares, inflamatorias, alergicas, pulmonares y fibroticas y cancer. | |
CL2014001861A1 (es) | Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia. | |
CL2012003322A1 (es) | Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer. | |
BRPI0912687A2 (pt) | uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia | |
CL2014003525A1 (es) | Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension. | |
CL2013000335A1 (es) | Forma altamente cristalina de valsartan; proceso para prepararla; composicion farmaceutica que la comprende y uso en el tratamiento de la hipertension. | |
AR082215A1 (es) | Composicion farmaceutica agradable al paladar | |
CL2012003265A1 (es) | Polisacarido de semillas de tamarindo para usarse en el tratamiento de enfermedades infecciosas; composicion farmacéutica y/o dermocosmética antiinflamatoria que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo. | |
CL2012001757A1 (es) | Compuestos derivados de 8-hidroxiquinolina-7-carboxamida; composicion farmaceutica; y su uso en el tratamiento de infecciones micoticas. | |
CL2014000792A1 (es) | Composicion para uso en la promocion de absorcion de magnesio y/o retencion de magnesio | |
BR112012029824A2 (pt) | métodos para o preparo de cloreto de glicopirrônio, cloreto de glicopirrônio, composição farmacêutica e uso de cloreto de glicopirrônio | |
SV2010003773A (es) | 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos | |
CR20130488A (es) | Derivados de tieno [2,3-d]pirimidina y su uso para tratar arritmia | |
CL2014000595A1 (es) | Extracto de cynara; composicion farmaceutica que lo contiene; y su uso para el tratamiento de hiperglucemia, hipercolesterolemia, hipertension y esteatosis hepatica. |